Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Fabienne Ricklin

Hans Hilpert

Alfred Binggeli

Uwe Grether

Patrizio Mattei

Johannes Aebi

Wolfgang Haap

Luke Green

Narendra Panday

Markus Boehringer

Olivier Roche

Stephan Roever

Katrin Groebke Zbinden

Hans Peter Maerki

Guido Hartmann

Bernd Kuhn

Mark Rogers-Evans

Peter Mohr

Hans-Peter Maerki

Markus Meyer

Matthias Heinrich Nettekoven

Jens-Uwe Peters

Henrietta Dehmlow

Robert Narquizian

Holger Kuehne

Georges Hirth

Tanja Schulz-Gasch

Aurelia Conte

Atsushi Kimbara

Roland Humm

Jean-Michel Adam

Jacques Himber

Sabine Hoves

Didier Rombach

Constantinos G Panousis

Nicole A Kratochwil

Luca Claudio Gobbi

Daniel Hunziker

Paul Hebeisen

Alexander Mayweg

Thomas Luebbers

David Banner

Hans Iding

Beat Wirz

Harald Mauser

Christoph Martin Stahl

Bernd Michael Loeffler

Lilli Anselm

Matthias Valentin Westphal

Beat Frei

Dietmar Knopp

Stefan Thomi

Peter Zahm

Katrin Gröbke Zbinden

Matthias Nettekoven

Constantinos Panousis

The invention relates to compound of formula (I) wherein Rto Rare as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Pyridine derivatives

The invention relates to a compound of formula (I) wherein Ato Aand Rto Rare defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Pyrazol derivatives

This invention relates to novel 4-amino-imidazoquinoline compounds of the formula 

4-amino-imidazoquinoline compounds

The invention relates to a compound of formula (I) wherein Rto Rare defined as in the description and in the claims. The compound of formula (I) is a CB2 agonist and can be used as an active ingredient in a medicament. 

Pyridine-2-amides useful as CB2 agonists

The present invention relates to compounds of formula I, wherein Rto Rare defined in the description and claims, and to pharmaceutically acceptable salts thereof. The present invention relates also to the manufacture of said compounds, pharmaceutical compositions containing them and methods for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as dyslipidemia, atherosclerosis and cardiovascular diseases.

3-pyridine carboxylic acid hydrazides

This invention relates to dihydropyrimidinones of the formula wherein X and Rto Rare as defined in the description, as well as pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the treatment or prevention of diseases such as diabetes.

Dihydropyrimidinones

The invention is concerned with novel heteroaryl carboxamide derivatives of formula (I), wherein m, X, Y, R, R, Rand Rare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.

Heteroaryl carboxamide derivatives

The invention is concerned with novel biaryl derivatives of formula (I), wherein m, R, R, R, X, Xand Xare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.

Biaryl derivatives

The invention is concerned with novel heterocyclyl compounds of formula (I): wherein A, X, R, R, R, R, R, R, R, R, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and may be used as medicaments.

Heterocyclyl compounds

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y, Y, Y, R, R, R, R, R, R, R, R, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y, R, R, R, R, R, R, R, R, m and n are as herein defined, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

Heterocyclic compounds

The invention is concerned with novel pyrazol derivatives of formula (I), wherein R, R, R, R, X and Y are as defined herein, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor and/or CCR-5 receptor and can be used as medicaments.

The invention is concerned with novel imidazole derivatives of formula (I), wherein m, E, R, R, R, R, R, Rand Rare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.

Imidazole derivatives

The invention is concerned with novel aza-pyridopyrimidinone derivatives of formula (I): wherein R, R, R, R, R, X, X, X, Y, Z, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used in treating or preventing diseases which are modulated by HM74A agonists.

Aza-pyridopyrimidinone derivatives

Growing community of inventors

Hombourg, France

Fabienne Ricklin